Update: FDA Transparency Task Force -- Update
>
The U.S. Food and Drug Administration (FDA) has a Transparency Task Force that is developing proposals to make the agency's operations more transparent, useful, and understandable to the public, while
protecting personal information and corporate trade secrets. The Task Force is currently in Phase II, examining public disclosure policies.
If you would like to see more information from FDA become available online, or would like to see currently available information made more useful, you will want to review and comment on the draft public disclosure proposals. Review the 21
draft proposals [PDF] concerning adverse event reports,
investigational applications, recall terminations, and other FDA
information.
The Task Force will take public comments on this topic until 20 July 2010. FDA released its request for comments in today's Federal Register, 75 Fed.Reg. 28622-28623 (21 May 2010). Instructions for commenting appear in the ADDRESSES section of the request. Further instructions are under the heading "III. Request for Comments". All comments are to reference the docket number, FDA–2009–N–0247, and the ordinal number assigned to the proposal in the draft proposal document.
Also see:
New
England Journal of Medicine Article, Perspective: Transparency at the
U.S. Food and Drug Administration [PDF]
Recent Comments